Glaucoma Market Trends
DelveInsight’s Glaucoma Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.
LAS VEGAS, NV, UNITED STATES, February 18, 2025 /EINPresswire.com/ --
DelveInsight’s “Glaucoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glaucoma Market Forecast
Some of the key facts of the Glaucoma Market Report:
• The Glaucoma market size was valued approximately USD 4,196 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In November 2024, MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company based in San Diego, revealed the results of its Phase 2b clinical trial for LL-BMT1. This trial utilized a novel 3D-printed, drug-eluting contact lens designed to deliver bimatoprost and hyaluronic acid for sustained treatment. The trial successfully met all Phase 2b endpoints. Dr. Ian Ben Gaddie presented these findings at the American Academy of Optometry’s annual meeting in Indianapolis, emphasizing LL-BMT1's potential as an innovative solution for managing mild to moderate glaucoma while enhancing contact lens comfort and alleviating dry eye symptoms.
• In October 2024, At the American Academy of Ophthalmology (AAO) 2024 conference held in Chicago, Illinois, findings from a Phase II study evaluating the safety of Neurotech Pharmaceuticals’ NT-501 encapsulated cell therapy, which secretes ciliary neurotrophic factor (CNTF), were presented. The results were shared by Alexandria M. Dominguez, MS, a research assistant at the Byers Eye Institute at Stanford University. The study indicated that the CNTF-secreting implants were well-tolerated by patients with primary open-angle glaucoma, with no severe adverse events reported. This therapy showed promising potential in managing intraocular pressure (IOP) and supporting retinal health, both of which are essential for effective glaucoma treatment.
• DelveInsight's analysis reveals that there were approximately 7,219 thousand diagnosed prevalent cases of Glaucoma in the 7MM in 2023, with expectations for a significant compound annual growth rate (CAGR) throughout the forecast period from 2024 to 2034.
• In 2023, Germany had the highest number of diagnosed prevalent glaucoma cases among the EU4 and the UK, with around 710 thousand cases, while Spain had the lowest with approximately 514 thousand cases. The number of cases is expected to increase in the EU4 and the UK.
• In 2023, the total number of prevalent glaucoma cases in the 7MM was 17,029 thousand, and this number is expected to rise during the study period from 2020 to 2034.
• The estimates indicate that the diagnosed prevalent population of glaucoma in Japan was 1,617 thousand cases in 2023.
• Key Glaucoma Companies: SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Bayer, Alcon Research, Pfizer, Merck Sharp & Dohme LLC, Quark Pharmaceuticals, and others
• Key Glaucoma Therapies: STN-1012600, PDP-716, PRO-122, EYBELIS/Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, Aflibercept (Eylea, BAY 86-5321), Travoprost, timolol/dorzolamide, QPI-1007, and others
• Glaucoma can impact individuals of both genders, but the ratio of male to female Glaucoma patients indicates a higher prevalence among females. In 2022, there were approximately 3,234,796 cases of Glaucoma among males and 3,810,646 cases among females.
• The Glaucoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glaucoma pipeline products will significantly revolutionize the Glaucoma market dynamics.
Glaucoma Overview
Glaucoma is a group of eye conditions that damage the optic nerve, which is essential for good vision. This damage is often caused by abnormally high pressure in the eye, though it can also occur with normal eye pressure. If left untreated, glaucoma can lead to permanent vision loss or blindness.
Get a Free sample for the Glaucoma Market Report:
https://www.delveinsight.com/report-store/glaucoma-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr
Glaucoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Glaucoma Epidemiology Segmentation:
The Glaucoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
• Total Prevalence of Glaucoma
• Prevalent Cases of Glaucoma by severity
• Gender-specific Prevalence of Glaucoma
• Diagnosed Cases of Episodic and Chronic Glaucoma
Download the report to understand which factors are driving Glaucoma epidemiology trends @ Glaucoma Epidemiology Forecast
Glaucoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glaucoma market or expected to get launched during the study period. The analysis covers Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Glaucoma Therapies and Key Companies
• STN-1012600: Santen Pharmaceutical
• NCX-470: Nicox Ophthalmics
• TRS01: Tarsier Pharma
• PDP-716: SPARC
• PRO-122: Laboratories Sophia
• EYBELIS/Omidenepag isopropyl/DE-117: Santen Pharmaceutical
• DE-130A: Santen Pharmaceutical
• Sepetaprost (DE-126/ONO9054): Santen Pharmaceutical
• Nyxol: Ocuphire Pharma
• K-232: Kowa
• Aflibercept (Eylea, BAY 86-5321): Bayer
• Travoprost: Alcon Research
• Timolol: Pfizer
• timolol/dorzolamide: Merck Sharp & Dohme LLC
• QPI-1007: Quark Pharmaceuticals
Glaucoma Market Strengths
• Rising prevalence of Glaucoma resulting in demand for improved treatments.
• Growing awareness about the importance of early detection to reduce the disease burden contributes to increased screening and diagnosis rates.
• New drug-delivery systems offer the hope of improved therapeutic outcomes by dealing with the problem of patient compliance and therapeutic adherence.
Glaucoma Market Opportunities
• With increasing awareness and improving healthcare infrastructure, the glaucoma market has growth potential in emerging markets.
• Collaboration between pharmaceutical companies, medical device manufacturers, and healthcare providers will drive innovation and comprehensive treatment approaches.
Scope of the Glaucoma Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Glaucoma Companies: SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Bayer, Alcon Research, Pfizer, Merck Sharp & Dohme LLC, Quark Pharmaceuticals, and others
• Key Glaucoma Therapies: STN-1012600, PDP-716, PRO-122, EYBELIS/Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, Aflibercept (Eylea, BAY 86-5321), Travoprost, timolol/dorzolamide, QPI-1007, and others
• Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies
• Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Glaucoma Unmet Needs, KOL’s views, Analyst’s views, Glaucoma Market Access and Reimbursement
To know more about Glaucoma companies working in the treatment market, visit @ Glaucoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Glaucoma Market Report Introduction
2. Executive Summary for Glaucoma
3. SWOT analysis of Glaucoma
4. Glaucoma Patient Share (%) Overview at a Glance
5. Glaucoma Market Overview at a Glance
6. Glaucoma Disease Background and Overview
7. Glaucoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Glaucoma
9. Glaucoma Current Treatment and Medical Practices
10. Glaucoma Unmet Needs
11. Glaucoma Emerging Therapies
12. Glaucoma Market Outlook
13. Country-Wise Glaucoma Market Analysis (2020–2034)
14. Glaucoma Market Access and Reimbursement of Therapies
15. Glaucoma Market Drivers
16. Glaucoma Market Barriers
17. Glaucoma Appendix
18. Glaucoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
